Core Viewpoint - The article discusses the impact of the "3·15" event on the exosome industry, highlighting the exit of many gray market players and the increased interest from investors in legitimate companies within the sector [2][3]. Group 1: Industry Overview - The exosome industry is recognized as a high-tech field with significant application potential, particularly in medical diagnostics and drug delivery [3][10]. - Following the "3·15" event, many companies involved in gray market practices have rapidly exited, while leading firms are experiencing a surge in investor interest [3][4]. Group 2: Company Activities - Suzhou Yihang Biotechnology, a leading company in the exosome field, has been actively engaging with investors, receiving nearly 100 million yuan in interest from various capital sources [5]. - Shidekexuo, a newly established company focused on exosome innovation drugs, is also attracting attention from government funds across multiple provinces [5]. Group 3: Regulatory Environment - Currently, no exosome drugs have been approved globally, with companies primarily in the early stages of clinical trials [15]. - The Chinese regulatory landscape is evolving, with recent drafts indicating that extracellular vesicles may be classified as "cell-derived biological products," providing clearer pathways for commercialization [20][21]. Group 4: Market Applications - Exosomes are being explored for various applications, including cancer diagnostics, with notable products like the ExoDx test for prostate cancer and a recently approved ovarian cancer detection kit in China [11][13]. - The potential for exosomes in cosmetic applications exists, although regulatory restrictions in China limit the use of human-derived exosomes in cosmetics [16]. Group 5: Investment Trends - The article notes a shift in investment focus towards companies that are genuinely engaged in scientific research and industrialization, as the market seeks to avoid the pitfalls of substandard products [21]. - The increased attention from diverse sectors, including e-commerce and fashion, indicates a growing recognition of the exosome industry's potential [21].